Italian Pharmacological Society is Promising a Drug to Treat Coronavirus
Every day drugs appear that can counteract the advance of the new coronavirus. Today it is the turn of gabesate, a molecule used for the treatment of pancreatitis. According to the Italian Pharmacological Society, the molecule has three fundamental effects for the treatment of coronavirus infection and its complications.
In addition to pancreatitis, mesylate gabesate is used for the treatment of disseminated intravasal coagulation and as an anticoagulant in hemodialysis.
“Today we know that the Sars-CoV-2 virus enters cells by exploiting a protein, present within them, called TMPRSS2 underline Giorgio Racagni, president of the SIF and Annalisa Capuano, clinical pharmacologist at the University of Campania Vanvitelli and member of the SIF, there is a molecule capable of simultaneously carrying out three fundamental activities for the treatment of the infection and its complication.
This is gabesate, a molecule belonging to the category of serpins (serine protease inhibitors): in clinical practice it is used in the form of mesylate gabesate (trade name Foy) for the treatment of pancreatitis, disseminated intravasal coagulation and as an anticoagulant in hemodialysis . “Today we know that the Sars-CoV-2 virus enters cells by exploiting a protein, present inside them, called TMPRSS2 – underline Racagni and Capuano -. This protein could be a target for any therapeutic interventions capable of defeating the infection that causes Covid-19. German researchers have isolated the Sars-CoV-2 virus from a patient and tested a molecule very similar to gabesate on it, realizing that it manages to block the entry of the virus into lung cells. Not only. Gabesate reduces the production of inflammatory cytokines, such as the tumor necrosis factor alpha (TNFa) “.
“The molecule has a marked anti-inflammatory activity and possesses antiplatelet and anticoagulant powers – the two experts continue -. Many Covid-19 patients have important thromboembolisms (hence the use of an anticoagulant, enoxaparin, in many hospitals) and, also for this reason, they often go to intensive care and are intubated. The main problem with Covid-19 is the marked immune reaction that destroys the cells where the virus has managed to enter. And ventilatory assistance probably does not produce improvement if the blood does not reach the lungs. CID (disseminated intravascular coagulation) could therefore be the complication that determines the worst outcomes. In conclusion, to summarize, we have a drug that potentially blocks the entry of the virus into lung cells, has an important antiplatelet and anticoagulant activity and is anti-inflammatory “. In Italy it is sold by Sanofi Aventis under the trade name of Foy, in the form of an intravenous infusion vial. The Pharmacology Society stresses that the use of gabesate for Covid-19 is only a pharmacological hypothesis that must be verified by the scientific and clinical world. The Society of Pharmacology is evaluating the possibility of starting an experimentation (subject to authorization by the Medicines Agency and the Ethical Committee of the Spallanzani Institute) at some Italian hospitals.
Drug to Treat Coronavirus - /10
Italian Pharmacological Society is Promising a Drug to Treat Coronavirus.